Product Images Potassium Citrate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 5 images provide visual information about the product associated with Potassium Citrate NDC 72865-191 by Xlcare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
10mEq
XLcare Pharmaceuticals Inc. sells Potassium Citrate Extended-Release Tablets, USP, containing 10 mEq (1080 mg) per tablet. The tablets are uncoated, capsule shaped, and off-white to tan yellowish in color. Each tablet is debossed with ‘T400 on one side and plain on the other side. The tablets are supplied in a container with a child-resistant closure. The recommended storage temperature for the tablets is 20°C to 25°C (68°F to 77°F), with occasional excursions allowed between 15°C to 30°C (59°F to 86°F). These tablets are available by prescription only, and the package insert should be read for dosage information. XLcare Pharmaceuticals Inc. manufactured it for Ascent Pharmaceuticals Inc. at Central Islip, NY 11722, and sold under NDC 72865-192-01.*
15mEq
This is a description of XLcare potassium citrate extended-release tablets in 15 mEq strength. The tablets are oval-shaped, uncoated, and colored white to tan yellowish. The dosage information can be found in the package insert. The tablets should be stored between 20°C and 25°C (68°F to 77°F), and the manufacturer is Ascent Pharmaceuticals, Inc. The tablets are produced for XLCare Pharmaceuticals, Inc.*
5mEq
This is a description of XLcare Potassium Citrate Extended-Release Tablets with a strength of 5 mEq. The tablets are uncoated and round-shaped, with 'T' on one side and '399' on the other. The package insert should be read for dosage information. The tablets should be stored in a tight container at a temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The tablets are manufactured by Ascent Pharmaceuticals, Inc. for XLCare Pharmaceuticals, Inc. and should only be dispensed with a prescription. *
Table 1.
Table 1 shows the effect of Potassium Citrate on patients with calcium oxalate nephrolithiasis. The table presents the number of stones formed per year in each group before and during treatment, as well as the percentage of remission and any decrease in the number of stones. Remission is defined as the percentage of patients who remained free of newly-formed stones during treatment.*
structure.
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.